Cardiology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Antiplatelet agents: Brilinta first to show reduction in cardiovascular death in patients with acute coronary syndromes

The presentation of the PLATO ( A Study of Platelet Inhibition and Patient Outcomes ), showed that Ticagrelor ( Brilinta ) reduced the rate of cardiovascular events ( cardiovascular death, myocardial infarction or stroke ) from 11.7% to 9.8% compared to Clopidogrel ( Plavix ) ( p